This study evaluates the peri-articular tranexamic acid injection in total knee arthroplasty which is an alternative route of administration for blood loss reduction. Half of participants will receive intravenous tranexamic acid injection, while the other half will receive peri-articular tranexamic acid injection during total knee arthroplasty.
Intravenous tranexamic acid (IV TXA) is one of the most effective agents in use for reducing blood loss following total knee arthroplasty (TKA) but its safety regarding venous thromboembolic events (VTEs) remains in question. The direct, local application of TXA may reduce systemic toxicity whilst maintaining good or better bleeding control compared to IV TXA. The topical application of TXA via Hemovac drains has been reported previously with good results. However, there are no data on peri-articular TXA injections during TKA.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Enrollment
60
750 mg of peri-articular TXA, prior to deflating the tourniquet and wound closure
750 mg of IV TXA, prior to deflating the tourniquet and wound closure
Orthopaedic department, Thammasat university hospital
Klongluang, Changwat Pathum Thani, Thailand
The volume of postoperative blood loss in the drain
Time frame: 48 hours after the operation
Changes from baseline hemoglobin concentrations
Time frame: 48 hours after the operation
unit of blood transfusion
Time frame: 48 hours after the operation
Knee diameter for swelling
Time frame: At 24 and 48 hours after the operation
number of patient with venous thromboembolism
Time frame: At 14 days after the operation
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.